Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Infect Drug Resist ; 15: 4127-4136, 2022.
Article in English | MEDLINE | ID: mdl-35937784

ABSTRACT

Purpose: This study was conducted to investigate antibody immune responses induced by BNT162b2 and AZD1222 human COVID-19 vaccines in Riyadh city, Saudi Arabia. Patients and Methods: ELISA was used to evaluate antibodies, against the SARS-CoV-2 spike S1 protein, in serum samples from 432 vaccinated individuals at six time points: pre-vaccination (baseline), post-prime, post-boost, 6-months, and 1 year post-vaccination, and 3 weeks post a third dose. Virus microneutralization assay was used to confirm antibody responses in a subset of samples. Results: Anti-SARS-CoV-2 spike IgG were detected in most subjects post-prime, reached a peak level post-boost, and remained at high level at the 6-month follow-up. At 1 year post-vaccine, the antibody levels were low but increased to a significant level higher than the peak following a third dose. The third dose was given at an average of 250 days after the second dose. The virus microneutralization assay confirmed the neutralization activity of the induced SARS-CoV-2 IgG antibodies. The vaccines induced higher IgG titres at post-prime (p=0.0001) and 6 months (p=0.006) in previously infected individuals. An increased interval between prime and boost, more than recommended time, appeared to enhance the IgG levels (p=0004). Moreover, the vaccines induced higher IgG levels in younger subjects (p=0.01). Conclusion: These data provide insights and build on the current understanding of immune responses induced by these two vaccines; and support a third boosting dose for these COVID-19 vaccines.

2.
Viruses ; 12(11)2020 10 27.
Article in English | MEDLINE | ID: mdl-33120981

ABSTRACT

MERS-CoV is a zoonotic virus that has emerged in humans in 2012 and caused severe respiratory illness with a mortality rate of 34.4%. Since its appearance, MERS-CoV has been reported in 27 countries and most of these cases were in Saudi Arabia. So far, dromedaries are considered to be the intermediate host and the only known source of human infection. This study was designed to determine the seroprevalence and the infection rate of MERS-CoV in slaughtered food-camels in Riyadh, Saudi Arabia. A total of 171 nasal swabs along with 161 serum samples were collected during the winter; from January to April 2019. Nasal swabs were examined by Rapid test and RT-PCR to detect MERS-CoV RNA, while serum samples were tested primarily using S1-based ELISA Kit to detect MERS-CoV (IgG) antibodies and subsequently by MERS pseudotyped viral particles (MERSpp) neutralization assay for confirmation. Genetic diversity of the positive isolates was determined based on the amplification and sequencing of the spike gene. Our results showed high prevalence (38.6%) of MERS-CoV infection in slaughtered camels and high seropositivity (70.8%) during the time of the study. These data indicate previous and ongoing MERS-CoV infection in camels. Phylogenic analysis revealed relatively low genetic variability among our isolated samples. When these isolates were aligned against published spike sequences of MERS-CoV, deposited in global databases, there was sequence similarity of 94%. High seroprevalence and high genetic stability of MERS-CoV in camels indicating that camels pose a public health threat. The widespread MERS-CoV infections in camels might lead to a risk of future zoonotic transmission into people with direct contact with these infected camels. This study confirms re-infections in camels, highlighting a challenge for vaccine development when it comes to protective immunity.


Subject(s)
Antibodies, Viral/blood , Camelus/virology , Coronavirus Infections/epidemiology , RNA, Viral/analysis , Spike Glycoprotein, Coronavirus/immunology , Abattoirs , Animals , Coronavirus Infections/virology , Disease Reservoirs/virology , Enzyme-Linked Immunosorbent Assay , Genetic Variation/genetics , Middle East Respiratory Syndrome Coronavirus/genetics , Middle East Respiratory Syndrome Coronavirus/isolation & purification , Prevalence , Saudi Arabia/epidemiology , Seroepidemiologic Studies , Spike Glycoprotein, Coronavirus/genetics
3.
Sci Rep ; 9(1): 16292, 2019 11 08.
Article in English | MEDLINE | ID: mdl-31705137

ABSTRACT

MERS-CoV seronegative and seropositive camels received a single intramuscular dose of ChAdOx1 MERS, a replication-deficient adenoviral vectored vaccine expressing MERS-CoV spike protein, with further groups receiving control vaccinations. Infectious camels with active naturally acquired MERS-CoV infection, were co-housed with the vaccinated camels at a ratio of 1:2 (infected:vaccinated); nasal discharge and virus titres were monitored for 14 days. Overall, the vaccination reduced virus shedding and nasal discharge (p = 0.0059 and p = 0.0274, respectively). Antibody responses in seropositive camels were enhancedby the vaccine; these camels had a higher average age than seronegative. Older seronegative camels responded more strongly to vaccination than younger animals; and neutralising antibodies were detected in nasal swabs. Further work is required to optimise vaccine regimens for younger seronegative camels.


Subject(s)
Camelus , Coronavirus Infections , Middle East Respiratory Syndrome Coronavirus , Viral Vaccines , Animals , Adenoviridae/immunology , Antibodies, Neutralizing/immunology , Antibodies, Viral/immunology , Camelus/immunology , Camelus/metabolism , Coronavirus Infections/prevention & control , Coronavirus Infections/veterinary , Coronavirus Infections/virology , Disease Outbreaks , Middle East Respiratory Syndrome Coronavirus/immunology , Middle East Respiratory Syndrome Coronavirus/metabolism , Middle East Respiratory Syndrome Coronavirus/pathogenicity , Middle East Respiratory Syndrome Coronavirus/physiology , Vaccination/methods , Viral Vaccines/immunology , Viral Vaccines/pharmacology , Zoonoses/epidemiology
4.
J Ayub Med Coll Abbottabad ; 22(3): 100-5, 2010.
Article in English | MEDLINE | ID: mdl-22338430

ABSTRACT

BACKGROUND: There is a dire need in the Arab world and Middle Eastern countries to reform the higher education, research policy and planning for improving the quality to meet the needs of modern society. The impact factor (IF) was developed in the 1960s by Eugene Garfield of the Institute for Scientific Information (ISI) in the USA. It has been extensively used for more than 40 years. The SCImago Journal Rank (SJR) indicator belongs to this new family of indicators based on eigenvector centrality was introduced since 2007. The SJR indicator is a size-independent metric aimed at measuring the current 'average prest (se text) per paper' of journals for use in research evaluation processes. METHODS: We present the status o the biomedical scientific research in the Middle Eastern countries through the newly developed SJR indicator showing some of the proposed ways that clearly can be applied for enhancing and development of that field in the Middle Eastern countries. RESULTS: During the period from 1996 to 2008, Northern America, Western Europe and Asiatic region are the major contributors of the scientific research Worldwide. In the Middle East, the prominent two main Arab countries are Egypt and Saudi Arabia, nevertheless, they need more planned strategies for optimal contribution to their Middle East, Arab region and the World, despite the tangible achievements of the Arab states in the higher education and scientific research during the last decade. CONCLUSION: The SJR is seemingly satisfactory for ranking the countries for their scientific contribution and impact.


Subject(s)
Biomedical Research , Journal Impact Factor , Arab World , Humans , Middle East
SELECTION OF CITATIONS
SEARCH DETAIL